Hibi, Toshifumi
Imai, Yuya
Senoo, Asako
Ohta, Kentaro
Ukyo, Yoshifumi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)
https://doi.org/10.1007/s00535-017-1326-1
Funding for this research was provided by:
Janssen Pharmaceutical KK
Article History
Received: 18 January 2017
Accepted: 25 February 2017
First Online: 21 March 2017
Compliance with ethical standards
:
: Yuya Imai, Asako Senoo, Kentaro Ohta and Yoshifumi Ukyo are employees of Janssen Pharmaceutical K.K., Japan. Dr. Toshifumi Hibi is a consultant for Janssen Pharmaceutical K.K., Japan.